London
· Delayed Price · Currency is GBP · Price in USD Atara Biotherapeutics Company Description
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom.
Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.
Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis.
The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research.
Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
| Country | United States |
| Founded | 2012 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 225 |
| CEO | Anhco Nguyen |
Contact Details
Address: 2380 Conejo Spectrum Street Thousand Oaks, Delaware 91320 United States | |
| Phone | 805 623 4211 |
| Website | atarabio.com |
Stock Details
| Ticker Symbol | 0HIY |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0465131078 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Anhco Nguyen | Chief Executive Officer |
| Eric Hyllengren | Chief Financial Officer |
| Eric Hyllengren | Chief Operating Officer |
| Alex Chapman | Head of Investor Relations |